

Application Serial No. 09/930,503
Amendment dated April 1, 2004
Reply to Office Action of October 1, 2003

Amendments to the Specification:

Please replace the paragraph appearing at page 7, lines 15-25 with the following amended paragraph:

The mechanisms of chronic pain and inflammation have begun to be elucidated. These can be associated with a wide range of conditions. Inflammation is a protective response of tissues affected by disease or injury, and characterized by redness, localized heat, swelling, pain, and possibly impaired function of the affected part. Recently a common mechanism for pain and inflammation has been identified in the substance P/tachykinin: neurokinin receptor 1 (NK-1) system. Substance P, $C_{63}H_{98}N_{18}O_{13}S$, is a neurotransmitter composed of amino acids, having the [[()]]sequence: Arg-Pro-Lys-Pro-Gly-Gln-Phe-Phe-Gly-Leu-Met- NH_2 (SEQ ID NO: 60). It is a member of the tachykinin family of peptide hormones that is present in nerve cells and in certain endocrine and immune cells. It induces contraction of intestinal smooth muscle and vasodilation; in the central nervous system, it acts as a neurotransmitter in the pain pathway.

Please replace the paragraph appearing at page 61, line 27 with the following amended paragraph:

1261 cttttcca (SEQ ID NO: 54)

Application Serial No. 09/930,503
Amendment dated April 1, 2004
Reply to Office Action of October 1, 2003

Please replace the table appearing at page 65, line 16 through page 66, line 2 with the following amended table:

<i>Sense</i>		<i>Antisense</i>	
ttc cac atc ttc ttc ctc ct	(SEQ ID NO 41 <u>22</u>)	agg agg aag aag atg tgg aa	(SEQ ID NO 60 <u>41</u>)
tga tga ttg tgg tgg tgt gca	(SEQ ID NO 42 <u>23</u>)	tgc aca cca cga caa tca tca	(SEQ ID NO 61 <u>42</u>)
gca agt ctc tgc caa gcg caa	(SEQ ID NO 43 <u>24</u>)	ttg cgc ttg gca gag act tgc	(SEQ ID NO 62 <u>43</u>)
ttg atg tag ggc agg agg aa	(SEQ ID NO 44 <u>25</u>)	ttc ctc ctg ccc tac atc aa	(SEQ ID NO 63 <u>44</u>)
tgc aca cca cga caa tca tca	(SEQ ID NO 45 <u>26</u>)	tga tga ttg tgg tgg tgt gca	(SEQ ID NO 64 <u>45</u>)
cat agt gtg att ccc act ac	(SEQ ID NO 46 <u>27</u>)	gta gtg gga atc aca cta	(SEQ ID NO 65 <u>46</u>)
atg cat agc caa tca cca gca	(SEQ ID NO 47 <u>28</u>)	tgc tgg tga ttg gct atg cat	(SEQ ID NO 66 <u>47</u>)
act ttg gtg gct gtg gct ga	(SEQ ID NO 48 <u>29</u>)	tca gcc aca gcc acc aaa gt	(SEQ ID NO 67 <u>48</u>)
gga tgt atg atg gcc atg ta	(SEQ ID NO 49 <u>30</u>)	tac atg gcc atc ata cat cc	(SEQ ID NO 68 <u>49</u>)
cat gga gta gat act ggc	(SEQ ID NO 50 <u>31</u>)	ttc gcc agt atc tac tcc gaa atg	(SEQ ID NO 69 <u>50</u>)
gaa gaa gtt gtg gaa ctt gca	(SEQ ID NO 51 <u>32</u>)	tgc aag ttc cac aac ttc ttc	(SEQ ID NO 70 <u>51</u>)
gta gac ctg ctg gat aaa ctt	(SEQ ID NO 52 <u>33</u>)	aag ttt atc cag cag gtc tac	(SEQ ID NO 71 <u>52</u>)
aca gta gat gat ggg gtt gta	(SEQ ID NO 53 <u>34</u>)	atg tac aac ccc atc atc cat tac	(SEQ ID NO 72 <u>53</u>)
gtg tac aga tag tag gct t	(SEQ ID NO 54 <u>35</u>)	aag cct act atc tgt aca c	(SEQ ID NO 73 <u>54</u>)
cct cct gtc tgg ctt tag aa	(SEQ ID NO 55 <u>36</u>)	ttc taa agc cag aca gga gg	(SEQ ID NO 74 <u>55</u>)
aac cca tac tga ccc ttt t	(SEQ ID NO 56 <u>37</u>)	aaa agg gtc agt atg ggt t	(SEQ ID NO 75 <u>56</u>)
caa gga tgg aat gtt ttc cct	(SEQ ID NO 57 <u>38</u>)	agg gaa aac att cca tcc ttg	(SEQ ID NO 76 <u>57</u>)
tct cta cct gaa gaa gtt	(SEQ ID NO 58 <u>39</u>)	aac ttc ttc agg tag aga	(SEQ ID NO 77 <u>58</u>)
ttc gaa atg gat aac gtc ctc	(SEQ ID NO 59 <u>40</u>)	gag gac gtt atc cat ttc gaa	(SEQ ID NO 78 <u>59</u>)

Please delete the sequence listing filed with the application.

Application Serial No. 09/930,503
Amendment dated April 1, 2004
Reply to Office Action of October 1, 2003

Please add the new sequence listing included with this amendment to the specification on a new page immediately following the Abstract.